SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

A sharp AVAX rebound is drawing attention around the institutional-adoption narrative, particularly traders focus on reported NYSE/ICE testing of Avalanche for tokenized securities and expanded brokerage access. Bulls view this as validation for real-world-asset growth, while skeptics argue the move is a pump-and-dump and cite weak fee revenue and token inflation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Escalating U.S.-Iran tensions, potential military action or a negotiated deal, and related risks to the Strait of Hormuz and oil supplies are dominating discussion around SPY. Traders are divided, with some expecting higher volatility and downside from energy inflation and rising yields, while others argue a ceasefire or dealand resilient futurescould support a continued rally.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Speculation around the U.S. CLARITY Act and broader crypto regulatory treatment is driving attention, with traders debating whether passage would support HBAR and other altcoins or whether delays and failure would trigger another selloff. The discussion is amplified by HBARs choppy rebound and resistance, while some holders cite Hederas institutional partnerships and network growth as longer-term support despite limited price follow-through.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Renewed U.S.-Iran and Houthi-Saudi tensions, with potential oil-supply disruption, are driving heavy debate around QQQs near-term direction. Bulls point to resilient futures and continued semiconductor/AI momentum, while bears warn that higher oil prices, Treasury yields and weak market breadth could trigger a pullback.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

A rebound through a key round-number resistance level has renewed attention around ALGO, with traders citing stronger volume, bullish chart setups and a potential altcoin-season rotation. Bullish participants also point to new leadership and post-quantum network upgrades, while skeptics argue the move may fade amid weak adoption, dilution concerns and recurring selloffs.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

The launch of confidential perpetual contracts powered by Hyperliquid is being cited as the immediate catalyst behind NEARs sharp rally, with traders highlighting privacy for leveraged on-chain trading. The community is broadly bullish and pointing to NEARs AI, interoperability and privacy positioning, although some traders argue the move is mainly momentum, short covering or a liquidity-driven pump.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Geopolitical risk around the Iran conflict, Houthi attacks, Strait of Hormuz shipping and damage to Saudi oil infrastructure is driving intense crude and USO discussion. Traders remain split, with bulls citing potential supply disruptions while bears argue that de-escalation, pipeline restarts, inventory builds and demand destruction could unwind the risk premium.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Anticipation around Coherents PhotonLink platform unveiling at ECOC, alongside strong AI data-center demand for optical connectivity and Nvidia-related supply ties, is driving attention. Traders are broadly bullish on a recovery, though some caution that resistance, profit-taking and sector volatility could limit follow-through.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Attention centers on REalloys selection for exclusive negotiations with the U.S. Army to develop heavy rare-earth processing at Utahs Tooele Army Depot, alongside its broader strategy to build a non-Chinese rare-earth magnet supply chain ahead of 2027 defense-sourcing requirements. Bullish traders cite the defense-policy backdrop, strategic partnerships and reported institutional interest, while skeptics focus on execution risk, dilution, limited current production and the absence of recent company updates.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Elevated crude prices and supply-risk concerns from Middle East tensions, including attacks on Saudi energy infrastructure and disruption around the Strait of Hormuz, are driving attention to Exxon Mobil and other major energy stocks. Traders largely view the oil rally as a tailwind for upstream cash flow, while others warn that de-escalation or a return of disrupted supply could unwind the geopolitical premium and pressure shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Bolt Biotherapeutics Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

BOLT Bolt Biotherapeutics Inc

Fundamentals

Latest BOLT News